Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Part I (main cohort) - Primary Trial Objectives: 1. To assess the efficacy of two doses of MK-8931 on cognition in subjects with mild to moderate AD. 2. To assess the efficacy of two doses of MK-8931 on functional ability in activities of daily living in subjects with mild to moderate AD. 3. To assess the safety and tolerability of three doses of MK-8931 in the treatment of subjects with mild to moderate AD. Part II (extension) - Primary Extension Trial Objectives: 1. To evaluate the safety and tolerability of MK-8931 in the long term treatment of mild to moderate Alzheimer’s Disease 2. To compare the efficacy of MK-8931 on cognition and functional ability in activities of daily living in subjects with mild to moderate AD in subjects administered MK-8931 for 24 months to that of subjects administered placebo for 18 months followed by MK-8931 for 6 months.
Critère d'inclusion
- mild to moderate Alzheimer's Disease